Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
DJ Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
By Cecilia Butini
Shares in French biopharmaceutical group Ipsen rose on Wednesday after the company said the European Commission has given the green light to the company's drug Cabometyx in combination with Bristol Myers Squibb Co.'s Opdivo for the treatment of renal cell carcinoma, a type of kidney cancer.
At 0900 GMT, Ipsen shares traded 4.4% higher at EUR73.05.
The company said the EU approval is based on results from a phase-3 trial named CheckMate-9ER, whose primary endpoint was the median progression-free survival in patients receiving the drug combination.
Progression-free survival--which is understood as the time after treatment that a patient can live without the disease worsening--was observed as doubling in patients receiving the drug combination compared with those receiving another, previously approved drug.
EU approval means the drug combination can be marketed for renal cell carcinoma in EU member states, Norway, Liechtenstein and Iceland, while the U.S. already granted approval in January, Ipsen said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 31, 2021 05:08 ET (09:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
DJ Ipsen在歐盟批准腎癌藥物組合後交易走高
By Cecilia Butini
塞西莉亞·布蒂尼(Cecilia Butini)
Shares in French biopharmaceutical group Ipsen rose on Wednesday after the company said the European Commission has given the green light to the company's drug Cabometyx in combination with Bristol Myers Squibb Co.'s Opdivo for the treatment of renal cell carcinoma, a type of kidney cancer.
法國生物製藥集團益普森(Ipsen)股價週三上漲，此前該公司表示，歐盟委員會已批准該公司的藥物Cabometyx與百時美施貴寶(Bristol Myers Squibb Co.)的Opdivo聯合用於治療腎癌，腎癌是腎癌的一種。
At 0900 GMT, Ipsen shares traded 4.4% higher at EUR73.05.
格林威治時間0900時，Ipsen股價上漲4.4%，至73.05歐元。
The company said the EU approval is based on results from a phase-3 trial named CheckMate-9ER, whose primary endpoint was the median progression-free survival in patients receiving the drug combination.
該公司表示，歐盟的批准是基於名為CheckMate-9ER的3期試驗的結果，該試驗的主要終點是接受聯合藥物治療的患者的中位無進展生存率。
Progression-free survival--which is understood as the time after treatment that a patient can live without the disease worsening--was observed as doubling in patients receiving the drug combination compared with those receiving another, previously approved drug.
無進展存活率--被認為是患者在治療後可以存活而不會惡化的時間--被觀察到，與接受另一種先前批准的藥物的患者相比，接受這種藥物組合的患者增加了一倍。
EU approval means the drug combination can be marketed for renal cell carcinoma in EU member states, Norway, Liechtenstein and Iceland, while the U.S. already granted approval in January, Ipsen said.
Ipsen説，歐盟的批准意味着該藥物組合可以在歐盟成員國、挪威、列支敦士登和冰島銷售治療腎癌的藥物，而美國已經在1月份批准了這種藥物。
Write to Cecilia Butini at cecilia.butini@wsj.com
寫信給塞西莉亞·布蒂尼(Cecilia Butini)，電子郵件：cecilia.butini@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
March 31, 2021 05:08 ET (09:08 GMT)
2021年3月31日東部時間05：08(格林尼治標準時間09：08)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧